Healthcare Industry News: DuraHeart
News Release - September 6, 2007
Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
ANN ARBOR, Mich., Sept. 6 (HSMN NewsFeed) -- Terumo Heart Inc. announced today that it is planning a European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland on September 17, 2007.The EACTS meeting will mark the official launch of the DuraHeart LVAS. The device has been on the market in Europe for several months and is experiencing significant interest since achieving a CE Mark earlier in the year.
The DuraHeart LVAS is a 3rd generation circulatory support device with full magnetic levitation, intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is the only approved implantable Left Ventricular Assist System combining a centrifugal pump with magnetic levitation of the impeller, providing exceptional reliability and minimizing the potential for blood damage and thrombus. The DuraHeart System is not available in the United States.
Terumo Heart Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for the heart failure patient. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products.
Contact: Mark White, Marketing Manager, Terumo Heart Inc., Ann Arbor, Michigan, USA on (734) 741-6262 or mark.white@terumomedical.com.
Source: Terumo Heart
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
